OncoMatch/Clinical Trials/NCT07056790

Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer

Is NCT07056790 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including 68Ga-PSMA-CYC and CYC for prostate ca.

Phase 1/2RecruitingFirst Affiliated Hospital of Fujian Medical UniversityNCT07056790Data as of May 2026

Treatment: 68Ga-PSMA-CYC · CYC — 68Ga-PSMA-CYC is a novel radiotracer targeting PSMA. In this study, we investigated the safety, biodistribution, radiation dosimetry of 68Ga-PSMA-CYC PET/CT in patients with prostate cancer, and performed a head-to-head comparison with 68Ga-PSMA-617 and 68Ga-PSMA-11 to evaluate its diagnostic performance.

Check if I qualify

Extracted eligibility criteria

Biomarker criteria

Required: FOLH1 imaging

68Ga-PSMA-CYC PET Imaging

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify